A new cholesterol-lowering drug from Sanofi and Regeneron has the potential to become a $3-billion-dollar-plus blockbuster, according to analysts awaiting imminent late-stage trial results.
Read the article here
Sanofi cholesterol drug touted as potential $3 billion blockbuster
